Business Wire

Seoul Semiconductor: Everlight Convicted for Stealing World-First Technology

26.8.2025 15:00:00 CEST | Business Wire | Press Release

Share

The Supreme Court of Korea has recently upheld a lower court ruling convicting Taiwan-based Everlight Electronics Co., Ltd. of violating the Act on Prevention and Protection of Industrial Technology for misappropriating Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890)’s patented LED technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826901820/en/

[Table] Summary of Seoul Semiconductor vs. Everlight Lawsuits (Image: Seoul Semiconductor)

Everlight was indicted for bribing three former employees of Seoul Semiconductor to misappropriate core technologies developed over decades of R&D, including the world’s first No-wire second-generation LED technology and advanced UV LED technologies. The former employees who leaked the technologies were also sentenced to prison terms.

Although Everlight initially appealed its first-trial conviction for trade secret infringement, the appellate court determined that Seoul Semiconductor’s technologies went beyond ordinary trade secrets and qualified as advanced national industrial technologies under Korea’s Industrial Technology Protection Act, adding further charges. Last week, the Supreme Court upheld the lower court’s ruling, making the conviction final.

Industry experts view the Supreme Court’s ruling as a meaningful precedent that will foster research and development while advancing the quality of human life. The decision confirms that Korea’s criminal jurisdiction can be effectively applied to foreign companies, and that under the principle of dual liability, both individuals and corporations can be held accountable.

This ruling serves as a strong warning to both domestic and overseas companies attempting to steal technology, either directly or indirectly. At the same time, it is expected to encourage fair competition and creative innovation.

In addition to the technology theft litigation, Seoul Semiconductor has vigorously pursued Everlight’s patent infringements. Over the past seven years, the company has won all 16 patent lawsuits across five countries, securing court orders prohibiting sales and mandating the recall of infringing products. Seoul Semiconductor is closely tracking the enforcement of the rulings and making sure companies aren’t disregarding them to save costs.

Lee Chung-hoon, founder of Seoul Semiconductor and the son of a farmer, stated, “Birth may be unfair, but opportunity must be fair. When intellectual property rights are respected, they give hope to struggling young people and companies, foster creative innovation, and gradually improve people’s lives.”

He further emphasized, “We are determined to dedicate ourselves to research and development, choosing bold failure over mere survival. And we will respond resolutely, even at all costs, against companies that infringe on our patents.”

For the past 30 years, Seoul Semiconductor has dedicated itself to the research and development of optical semiconductors, amassing more than 18,000 patents—an unparalleled portfolio in the LED industry. These are not merely numbers; they include core technologies that define the second generation of the LED industry, such as the world’s first No-wire technology (essential for MicroLED display manufacturing) and the world’s first RGB 1-chip technology. Today, Seoul Semiconductor stands as the world’s No. 1 in LED backlight technology, No. 1 in UV LEDs, and No. 3 in the global LED industry overall, solidifying its position as a leading optical semiconductor company.

About Seoul Semiconductor
Seoul Semiconductor is the world’s third-largest global optoelectronics (LED) company, specializing in LED technology for over 30 years. With the vision of "Making the world clean, healthy, and beautiful through light," Seoul Semiconductor leads a new paradigm of light across various industries, including lighting, automotive, IT (such as backlighting), and its subsidiary, Seoul Viosys, which specializes in MicroLED, UV, Sensors, and Datacomm (SD).

Some of the groundbreaking technologies developed by Seoul Semiconductor include the world’s first innovative No-wire LED technology WICOP, the SunLike LED, which replicates natural sunlight spectrum, the high-voltage LED Acrich, the ultra-bright nPola LED (10 times brighter than conventional LEDs), the RGB one-chip MicroLED WICOP Pixel, and UV sterilization technology Violeds.

Seoul Semiconductor holds an impressive portfolio of over 18,000 patents, and in the last 20 years, the company has won over 100 cases in patent litigation across 8 countries. Believing that the patent system provides hope for young people and serves as a foundation for building a better world, the company is actively engaged in intellectual property protection. For more details, visit our official website (www.seoulsemicon.com or www.seoulviosys.com) and our social media channels (LinkedIn).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250826901820/en/

Contacts

Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye